These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The mechanism of osteoclast differentiation induced by IL-1. Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010 [TBL] [Abstract][Full Text] [Related]
9. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833 [TBL] [Abstract][Full Text] [Related]
10. Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival. Hwang YH; Lee JW; Hahm ER; Jung KC; Lee JH; Park CH; Rhee HS; Ryu JM; Kim HK; Yang CH Biochem Biophys Res Commun; 2005 Nov; 337(3):815-23. PubMed ID: 16213465 [TBL] [Abstract][Full Text] [Related]
11. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand. Shinmyouzu K; Takahashi T; Ariyoshi W; Ichimiya H; Kanzaki S; Nishihara T Biochem Biophys Res Commun; 2007 Mar; 354(2):447-52. PubMed ID: 17239341 [TBL] [Abstract][Full Text] [Related]
12. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790 [TBL] [Abstract][Full Text] [Related]
13. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114 [TBL] [Abstract][Full Text] [Related]
14. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251 [TBL] [Abstract][Full Text] [Related]
16. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600 [TBL] [Abstract][Full Text] [Related]